MCID: PRM163
MIFTS: 40

Primary Mediastinal Large B-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Primary Mediastinal Large B-Cell Lymphoma

MalaCards integrated aliases for Primary Mediastinal Large B-Cell Lymphoma:

Name: Primary Mediastinal Large B-Cell Lymphoma 58
Mediastinal Large B-Cell Lymphoma 70 32
Mediastinal Diffuse Large-Cell Lymphoma with Sclerosis 58
Primary Mediastinal Clear Cell Lymphoma of B-Cell Type 58
Large Cell Lymphoma of the Mediastinum 58
Med-Dlbcl 58

Characteristics:

Orphanet epidemiological data:

58
primary mediastinal large b-cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 32 C85.2
ICD10 via Orphanet 33 C83.3
UMLS via Orphanet 71 C0855152 C1292754
Orphanet 58 ORPHA98838
UMLS 70 C1292754

Summaries for Primary Mediastinal Large B-Cell Lymphoma

MalaCards based summary : Primary Mediastinal Large B-Cell Lymphoma, also known as mediastinal large b-cell lymphoma, is related to diffuse large b-cell lymphoma and lymphoma, hodgkin, classic. An important gene associated with Primary Mediastinal Large B-Cell Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Innate Immune System and T cell receptor signaling pathway. The drugs Decitabine and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include lung, thymus and b cells, and related phenotypes are homeostasis/metabolism and mortality/aging

Related Diseases for Primary Mediastinal Large B-Cell Lymphoma

Diseases in the Primary Mediastinal B-Cell Lymphoma family:

Primary Mediastinal Large B-Cell Lymphoma

Diseases related to Primary Mediastinal Large B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 diffuse large b-cell lymphoma 31.2 IRF4 CD274 BCL6
2 lymphoma, hodgkin, classic 30.5 STAT6 JAK2 IRF4 BCL6
3 gray zone lymphoma 30.5 PDCD1LG2 CD274 BCL6
4 primary mediastinal b-cell lymphoma 30.4 XPO1 STAT6 BCL6
5 b-cell lymphoma 30.4 STAT6 JAK2 IRF4 IL4I1 CD274 BCL6
6 marginal zone b-cell lymphoma 29.9 IRF4 BCL6
7 central nervous system lymphoma 29.8 PDCD1LG2 CD274 BCL6
8 mantle cell lymphoma 29.8 XPO1 CD274 BCL6
9 testicular lymphoma 29.5 PDCD1LG2 IRF4 CD274 BCL6
10 lymphoma 11.0
11 lymphoma, non-hodgkin, familial 10.7
12 mediastinal gray zone lymphoma 10.4
13 mucositis 10.4
14 hemopericardium 10.4
15 pericardial effusion 10.4
16 47,xyy 10.4
17 burkitt lymphoma 10.3
18 thrombophilia due to thrombin defect 10.3
19 follicular lymphoma 10.3
20 b-lymphoblastic leukemia/lymphoma 10.3
21 neutropenia 10.3
22 b-cell non-hodgkin lymphoma 10.3
23 nodular lymphocyte predominant hodgkin lymphoma 10.3
24 thymic carcinoma 10.2
25 seminoma 10.2
26 hypercarotenemia and vitamin a deficiency, autosomal dominant 10.1
27 multiple sclerosis 10.1
28 lymphoma, mucosa-associated lymphoid type 10.1
29 immune deficiency disease 10.1
30 thymoma, familial 10.1
31 reticuloendotheliosis, x-linked 10.1
32 pulmonary hypertension 10.1
33 anaplastic large cell lymphoma 10.1
34 covid-19 10.1
35 thymus lymphoma 10.1
36 thrombocytopenia 10.1
37 myeloproliferative neoplasm 10.1
38 relapsing-remitting multiple sclerosis 10.1
39 lung sarcoma 10.1
40 lipomatosis 10.1
41 thymoma 10.1
42 liposarcoma 10.1
43 aortic aneurysm 10.1
44 mediastinal lipomatosis 10.1
45 tricuspid valve insufficiency 10.1
46 peripheral nervous system disease 10.1
47 follicular dendritic cell sarcoma 10.1
48 thyroiditis 10.1
49 neuropathy 10.1
50 pulmonary embolism 10.1

Graphical network of the top 20 diseases related to Primary Mediastinal Large B-Cell Lymphoma:



Diseases related to Primary Mediastinal Large B-Cell Lymphoma

Symptoms & Phenotypes for Primary Mediastinal Large B-Cell Lymphoma

MGI Mouse Phenotypes related to Primary Mediastinal Large B-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.7 BCL6 CD274 IL4I1 IRF4 JAK2 PDCD1LG2
2 mortality/aging MP:0010768 9.5 BCL6 CD274 IL4I1 JAK2 PDCD1LG2 STAT6
3 neoplasm MP:0002006 8.92 IRF4 JAK2 PDCD1LG2 STAT6

Drugs & Therapeutics for Primary Mediastinal Large B-Cell Lymphoma

Drugs for Primary Mediastinal Large B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Decitabine Approved, Investigational Phase 1, Phase 2 2353-33-5 451668
2
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
3
Vinorelbine Approved, Investigational Phase 1, Phase 2 71486-22-1 60780 44424639
4
Zanubrutinib Approved, Investigational Phase 2 1691249-45-2
5
Etoposide Approved Phase 2 33419-42-0 36462
6
Daunorubicin Approved Phase 2 20830-81-3 30323
7
nivolumab Approved Phase 2 946414-94-4
8
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
9
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
10
rituximab Approved Phase 2 174722-31-7 10201696
11
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
12
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
13
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
14
Cortisone Experimental Phase 2 53-06-5 222786
15 Antimetabolites Phase 1, Phase 2
16 Protein Kinase Inhibitors Phase 2
17 Etoposide phosphate Phase 2
18 Immunoglobulins Phase 2
19 Antibodies Phase 2
20 Antibodies, Monoclonal Phase 2
21 Immunoconjugates Phase 2
22 Immunoglobulins, Intravenous Phase 2
23 Tubulin Modulators Phase 2
24 Antibiotics, Antitubercular Phase 2
25 Immunosuppressive Agents Phase 2
26
Liposomal doxorubicin Phase 2 31703
27 Antineoplastic Agents, Immunological Phase 2
28 Immunologic Factors Phase 2
29 Antirheumatic Agents Phase 2
30 Alkylating Agents Phase 2
31 Antimitotic Agents Phase 2
32 Anti-Bacterial Agents Phase 2
33 Hormone Antagonists Phase 2
34 glucocorticoids Phase 2
35 Hormones Phase 2
36 Antineoplastic Agents, Hormonal Phase 2
37 Anti-Inflammatory Agents Phase 2
38
Pembrolizumab Approved Phase 1 1374853-91-4
39
Nitric Oxide Approved Phase 1 10102-43-9 145068
40 omega-N-Methylarginine Phase 1
41
Arginine Investigational, Nutraceutical Phase 1 74-79-3 6322

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Combined Chemotherapy and PD-1 Antibody(SHR-1210) With or Without Low-dose Decitabine Priming for Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL):Two Stage, Phase I/II Trail Unknown status NCT03346642 Phase 1, Phase 2 Decitabine;GVD chemotherapy;SHR-1210
2 A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas Completed NCT01994850 Phase 1, Phase 2 brentuximab vedotin
3 A Phase II Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (PMLBCL) Completed NCT02423291 Phase 2 Brentuximab Vedotin
4 A Phase II Study of Pembrolizumab (MK-3475) in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS) Completed NCT02576990 Phase 2
5 Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma Completed NCT01965119 Phase 2 Ruxolitinib
6 A Phase II Study on the Safety and Efficacy of Zanubrutinib Combined With Tislelizumab in the Treatment of Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma and Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma Recruiting NCT04705129 Phase 2 Zanubrutinib;Tislelizumab
7 Phase 2 Study of Copanlisib in Combination With Nivolumab in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma Recruiting NCT03484819 Phase 2 Copanlisib Hydrochloride
8 Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase II Trial of DA-EPOCH-Rituximab in PMLBL Active, not recruiting NCT01516567 Phase 2 Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab
9 A Multicenter, Open-Label, Single-arm Phase II Study of LP002 in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma Not yet recruiting NCT04600947 Phase 2 LP002
10 A Phase II Study to Determine the Response Kinetics, Safety, and Efficacy of Brentuximab Vedotin and Nivolumab Alone and Then Combined With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone for Patients With Untreated Primary Mediastinal Large B-Cell Lymphoma Not yet recruiting NCT04745949 Phase 2 Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Prednisone
11 Phase II Study of CHOP/Rituxan Plus VELCADE in Mediastinal Large B-cell Lymphoma Terminated NCT00361621 Phase 2 bortezomib;Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
12 Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Primary Mediastinal Large B-cell Lymphoma, Renal Cell Carcinoma, Small Cell Lung Cancer, Microsatellite Instability-High/Mismatch Repair Deficient Cancer, or for the Treatment of Adult Patients With Unresectable or Metastatic Tumor Mutational Burden-High Solid Tumors Recruiting NCT03236935 Phase 1 L-NMMA;Pembrolizumab
13 A Phase 1 Clinical Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (KEYNOTE-A33) Recruiting NCT04317066 Phase 1 Pembrolizumab
14 Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL) Recruiting NCT04824950
15 IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL) Active, not recruiting NCT01599559

Search NIH Clinical Center for Primary Mediastinal Large B-Cell Lymphoma

Genetic Tests for Primary Mediastinal Large B-Cell Lymphoma

Anatomical Context for Primary Mediastinal Large B-Cell Lymphoma

MalaCards organs/tissues related to Primary Mediastinal Large B-Cell Lymphoma:

40
Lung, Thymus, B Cells, Bone Marrow, Myeloid, T Cells

Publications for Primary Mediastinal Large B-Cell Lymphoma

Articles related to Primary Mediastinal Large B-Cell Lymphoma:

(show top 50) (show all 327)
# Title Authors PMID Year
1
Mutational landscape of gray zone lymphoma. 61
32961552 2021
2
Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma. 61
33666656 2021
3
Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia? 61
33804850 2021
4
PIM Kinases Promote Survival and Immune Escape in Primary Mediastinal Large B-Cell Lymphoma through Modulation of JAK-STAT and NF-κB Activity. 61
33307035 2021
5
Characterization of DLBCL with a PMBL gene expression signature. 61
33684939 2021
6
Deauville score evaluation of interim PET/CT in primary mediastinal large B-cell lymphoma. 61
33758951 2021
7
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. 61
33523289 2021
8
Masquerading of COVID-19 Infection as Primary Mediastinal Large B-Cell Lymphoma 61
33491812 2021
9
Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S. 61
33616256 2021
10
Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. 61
32954856 2021
11
Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis. 61
33508568 2021
12
Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. 61
33285316 2021
13
Concurrent application of blinatumomab and haploidentical donor leukocyte infusions for refractory primary mediastinal large B-cell lymphoma. 61
33747421 2021
14
Expecting the unexpected - Primary mediastinal large B cell lymphoma presenting as huge lung parenchymal mass. 61
33717867 2021
15
Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. 61
32603413 2020
16
Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement. 61
33369766 2020
17
[Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis]. 61
33342160 2020
18
EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma. 61
32339368 2020
19
Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma. 61
32839159 2020
20
DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation. 61
32854650 2020
21
Nivolumab plus gemcitabine, dexamethasone, and cisplatin chemotherapy induce durable complete remission in relapsed/refractory primary mediastinal B-cell lymphoma: a case report and literature review. 61
32783492 2020
22
Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. 61
32850008 2020
23
Primary Mediastinal Large B-Cell Lymphoma in a Child Presenting With Superior Mediastinal Syndrome and Chylous Pleural and Pericardial Effusion. 61
30951026 2020
24
Radiation therapy in primary mediastinal large B-cell lymphoma treated with DA-R-EPOCH. 61
32695347 2020
25
Primary mediastinal large B-cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy. 61
32469086 2020
26
Presentation and management of primary mediastinal large B-cell lymphoma: a retrospective cohort analysis. 61
32233823 2020
27
Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report. 61
32577237 2020
28
Primary mediastinal large B cell lymphoma with coexisting aberrations of C-MYC and BCL-2: a case report and literature review. 61
31728727 2020
29
Gene expression profiling of gray zone lymphoma. 61
32516416 2020
30
Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. 61
32366834 2020
31
Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities. 61
31822802 2020
32
Recurrent Pleomorphic Myxoid Liposarcoma in a Patient With Li-Fraumeni Syndrome. 61
31559875 2020
33
[Clinical Characteristics and Prognosis of 56 Lymphoma Patients with Mediastinal Masses]. 61
32319385 2020
34
Relapsed/refractory primary mediastinal large B-cell lymphoma: a structured review of epidemiology, treatment guidelines and real-world treatment practices. 61
31951774 2020
35
Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel. 61
32055645 2020
36
Diagnostic utility of programmed cell death ligand 1 (clone SP142) in mediastinal composite lymphoma: A report of two cases. 61
31894883 2020
37
Diffuse large B-cell lymphoma variants: an update. 61
31735345 2020
38
A Primary Mediastinal Large B-Cell Lymphoma Patient With COVID-19 Infection After Intensive Immunochemotherapy: A Case Report. 61
32574278 2020
39
CD20+ T Cells in Primary Mediastinal Large B Cell Lymphoma Microenvironment. 61
31218821 2020
40
Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review. 61
32801876 2020
41
Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma. 61
31606909 2020
42
Comment: Is There a Role for Allogenic Hematopoietic Cell Transplantation in Primary Mediastinal Large B Cell Lymphoma? 61
31614199 2019
43
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. 61
31609651 2019
44
Successful Management of Primary Mediastinal Large B-cell Lymphoma during Pregnancy. 61
31391392 2019
45
Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. 61
31394277 2019
46
Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma. 61
31831043 2019
47
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. 61
31707975 2019
48
Primary Mediastinal Nodal and Extranodal Non-Hodgkin Lymphomas: Current Concepts, Historical Evolution, and Useful Diagnostic Approach: Part 1. 61
31567132 2019
49
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. 61
31398081 2019
50
Primary Mediastinal Large B-Cell Lymphoma: A Review for Radiologists. 61
31414888 2019

Variations for Primary Mediastinal Large B-Cell Lymphoma

Expression for Primary Mediastinal Large B-Cell Lymphoma

Search GEO for disease gene expression data for Primary Mediastinal Large B-Cell Lymphoma.

Pathways for Primary Mediastinal Large B-Cell Lymphoma

Pathways related to Primary Mediastinal Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 STAT6 PDCD1LG2 JAK2 IRF4 CD274 BCL6
2
Show member pathways
12.24 JAK2 IRF4 CD274
3
Show member pathways
12.22 STAT6 JAK2 IRF4
4 11.61 STAT6 PDCD1LG2 JAK2 IRF4 CD274 BCL6
5 11.51 STAT6 JAK2 IRF4 BCL6
6 11.39 STAT6 JAK2
7 11.25 PDCD1LG2 CD274 BCL6
8 11.18 XPO1 BCL6
9 11.15 STAT6 JAK2
10 11.12 STAT6 JAK2
11 11.06 STAT6 JAK2 IRF4 BCL6
12 11 JAK2 IRF4
13 10.94 XPO1 BCL6
14
Show member pathways
10.83 JAK2 IRF4
15 10.55 STAT6 IRF4

GO Terms for Primary Mediastinal Large B-Cell Lymphoma

Cellular components related to Primary Mediastinal Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.43 XPO1 STAT6 JAK2 IRF4 CD274 BCL6
2 endomembrane system GO:0012505 8.8 PDCD1LG2 JAK2 CD274

Biological processes related to Primary Mediastinal Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.62 PDCD1LG2 JAK2 IL4I1 CD274
2 interferon-gamma-mediated signaling pathway GO:0060333 9.57 JAK2 IRF4
3 positive regulation of T cell proliferation GO:0042102 9.56 PDCD1LG2 CD274
4 response to cytokine GO:0034097 9.55 STAT6 CD274
5 T cell costimulation GO:0031295 9.54 PDCD1LG2 CD274
6 negative regulation of T cell proliferation GO:0042130 9.52 PDCD1LG2 CD274
7 negative regulation of interferon-gamma production GO:0032689 9.51 PDCD1LG2 CD274
8 positive regulation of interleukin-10 production GO:0032733 9.49 IRF4 CD274
9 positive regulation of DNA binding GO:0043388 9.48 JAK2 IRF4
10 JAK-STAT cascade GO:0007259 9.46 STAT6 JAK2
11 negative regulation of interleukin-10 production GO:0032693 9.43 PDCD1LG2 CD274
12 positive regulation of cold-induced thermogenesis GO:0120162 9.43 STAT6 JAK2 IRF4
13 negative regulation of activated T cell proliferation GO:0046007 9.4 PDCD1LG2 CD274
14 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.37 STAT6 JAK2
15 cytokine-mediated signaling pathway GO:0019221 9.26 STAT6 JAK2 IRF4 BCL6
16 negative regulation of type 2 immune response GO:0002829 9.16 STAT6 BCL6
17 immune system process GO:0002376 9.1 PDCD1LG2 JAK2 IRF4 IL4I1 CD274 BCL6

Sources for Primary Mediastinal Large B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....